Juno Therapeutics Got Some Bad News

By Jason Carr

Standpoint Research analyst Ronnie Moas downgraded Juno Therapeutics (NASDAQ: JUNO) to Sell today. The company’s shares opened today at $41.12, close to its 52-week high of $44.60.

According to TipRanks.com, Moas is a 5-star analyst with an average return of 5.3% and a 69.1% success rate. Moas covers the Consumer Goods sector, focusing on stocks such as Mercer International Inc, Archer Daniels Midland, and Edgewell Personal Care.

Juno Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $39.

The company has a one year high of $44.60 and a one year low of $17.52. Currently, Juno Therapeutics has an average volume of 2.39M.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, and Robert T.